Results 191 to 200 of about 109,553 (260)

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

open access: yesBritish Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß   +3 more
wiley   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli   +4 more
wiley   +1 more source

Clinical spectrum and treatment of thyroid lymphoma: results of a cohort study of 61 patients. [PDF]

open access: yesFront Oncol
Li S   +10 more
europepmc   +1 more source

Tumor‐Derived Exosomal piR‐hsa‐28212 Promotes Lymphatic Metastasis in Breast Cancer

open access: yesCancer Science, EarlyView.
Breast cancer–derived exosomal piR‐hsa‐28212 promotes lymphangiogenesis and lymph node metastasis by activating VEGFC/VEGFR3 signaling. It stabilizes TBX1 mRNA in lymphatic endothelial cells and METTL3 protein in tumor cells, enhancing VEGFR3 expression and VEGFC secretion.
Yafen Wang   +7 more
wiley   +1 more source

Efficacy and safety of high doses of eltrombopag for treating adult immune thrombocytopenia: Results from a multicentre retrospective cohort study

open access: yes
British Journal of Haematology, EarlyView.
Salomé Dahan   +7 more
wiley   +1 more source

Pleiotropic Roles of FBXO11 in Tumorigenesis: Implications for Targeted Therapy

open access: yesCancer Science, EarlyView.
This complex comprises of scaffold CUL1, SKP1, RBX1 and FBXO11 receptor. The substrate is phosphorylated by specific kinase enzyme and recognized by the substrate recognition domain. FBXO11 targets numerous substrates for ubiquitination and degradation, FBXO11 substrates mainly include Snail, ZEB1, p53, BCL6, CDT2, CIITA, Cdc25a, hnRNPA2B1, SAMD1 and ...
Yuqi Zhang   +6 more
wiley   +1 more source

Diffuse Large B-Cell Lymphoma With Pulmonary and Gastric Involvement Mimicking Nontuberculous Mycobacterial Lung Disease. [PDF]

open access: yesRespirol Case Rep
Masuda K   +13 more
europepmc   +1 more source

Real‐World Safety and Efficacy of Pola‐R‐CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients

open access: yesCancer Science, EarlyView.
In this analysis of a diverse cohort of 500 patients with previously untreated DLBCL in a real‐world clinical setting, Pola‐R‐CHP demonstrated high response rates at end‐of‐treatment, which were consistent among the overall population, in patients > 80 years and regardless of International Prognostic Index status and cell of origin subtypes.
Takahiro Kumode   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy